Int J Gastrointest Interv 2019; 8(3): 116-122
Published online July 31, 2019 https://doi.org/10.18528/ijgii190010
Copyright © International Journal of Gastrointestinal Intervention.
Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea
Correspondence to:*Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153 Gyeongchun-ro, Guri 11923, Korea.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Postoperative bleeding is a common adverse event in endoscopic submucosal dissection (ESD) and may be life-threatening. Postoperative bleeding occurs frequently in patients treated with antithrombotic agents, including aspirin, antiplatelet agents, warfarin, and non-vitamin K-dependent oral anticoagulants. Due to the aging population and the increase in the risk of thromboembolic disease, the number of patients who require antithrombotic therapy has increased. To date, several clinical studies have been conducted and several global guidelines have been updated. Nevertheless, determining the optimal use of antithrombotic agents in patients undergoing ESD is still challenging, and recommendations for the use of these agents vary slightly across different guidelines. In this review, I summarized the current guidelines and discussed several ongoing issues with the management of antithrombotic agents in patients undergoing ESD.
Keywords: Anticoagulants, Antiplatelet agent, Antithrombotic agent, Aspirin, Endoscopic mucosal resection
Endoscopic submucosal dissection (ESD) is a minimally invasive technique, that is widely used for the management of early gastrointestinal tumors, especially in Asia.1–3 It has the advantage of providing higher
The concern for postoperative bleeding is even greater when patients taking antithrombotic agents require ESD. As the population ages and the risk of thromboembolic disease increases, the number of patients who require antithrombotic therapy also increases.15,16 Moreover, various antithrombotic medications, including aspirin, nonsteroidal anti-inflammatory drugs, adenosine diphosphate receptor/P2Y12 inhibitors, glycoprotein IIb/IIIa inhibitors, prostacyclin, thromboxane inhibitors, phosphodiesterase inhibitors, vitamin K antagonists, heparin, and non-vitamin K-dependent oral anticoagulants (NOAC), are available.17 To cope with these changes, many clinical studies are being conducted and several global guidelines are being updated.17–23 Additionally, a web-based application has recently been developed to help manage antithrombotic agents before endoscopy.24 Nevertheless, the use of antithrombotic agents in patients undergoing endoscopy is still complex and recommendations for the use of these agents vary slightly across different guidelines. In this review, I summarize the recommendations from recent guidelines and discuss several issues with the management of antithrombotic agents in patients undergoing ESD.
The major statements on antithrombotic agents that focus on ESD in the recent guidelines are summarized in Table 1.17–23 Most guidelines recommend the management of antithrombotic therapy according to the risk of bleeding during endoscopic procedures. However, in the American Society for Gastrointestinal Endoscopy (ASGE) guidelines published in 2009, the risk of bleeding due to ESD had not been rated but polypectomy was considered a high-risk procedure.18 Thus, we applied the following statement to ESD: “When high-risk procedures are planned, clinicians may elect to discontinue aspirin and/or nonsteroidal anti-inflammatory drugs for 5 to 7 days before the procedure, depending on the underlying indication for antiplatelet therapy.” In the ASGE guideline published in 2016, ESD was rated as a higher-risk procedure, similar to EMR and polypectomy.17 In this guideline many new statements were developed regarding the use of antiplatelet agents and anticoagulants. Summaries of the recommendations for the use of antiplatelet agents in high-risk procedures are: (1) low-dose aspirin may be continued during the perioperative period, (2) monotherapy with thienopyridine derivatives can be discontinued or switched to low-dose aspirin monotherapy during the perioperative period, and (3) dual antiplatelet therapy can be replaced with low-dose aspirin monotherapy during the perioperative period. Regarding anticoagulants, the guideline recommends that anticoagulants be discontinued during the perioperative period and replaced with heparin-bridge therapy in patients at a high risk of thromboembolic events. Compared to the previous version of the guideline, the 2016 ASGE guideline emphasized the continuation of low-dose aspirin during ESD.
In the European Society of Gastrointestinal Endoscopy (ESGE) guidelines published in 2011 and 2016, ESD, EMR, and polypectomy were considered high-risk procedures.19,20 In the 2011 ESGE guideline, discontinuation of all antiplatelet agents was recommended for both EMR and ESD if the patient was not at a high risk of thromboembolic events.19 In the 2016 ESGE guidelines, however, continuation of low-dose aspirin is recommended during ESD in patients undergoing dual antiplatelet therapy.20 Low-dose aspirin or P2Y12 receptor antagonist monotherapy can be discontinued during the perioperative period if patients are at a low risk of thromboembolic events. The recent guidelines also support the continuation of low-dose aspirin during ESD in patients at a high risk of thromboembolic events. For anticoagulation therapy, it is recommended that warfarin be discontinued in patients at a low risk of thromboembolic events and be replaced with low molecular weight heparin during the perioperative period in patients at a high risk of thromboembolic events.
The Japan Gastroenterological Endoscopy Society (JGES) guidelines published in 2014 also classified ESD, EMR, and polypectomy as high-risk procedures.21 The JGES guidelines support the continuation of low-dose aspirin during ESD in patients at a high risk of thromboembolic events. The discontinuation of thienopyridine derivatives is recommended during ESD. However, their replacement with aspirin or cilostazol is recommended in patients at a high risk of thromboembolic events. Additionally, it is recommended that warfarin and dabigatran be replaced with heparin during the perioperative period. In 2018, the JGES published further statements concerning anticoagulants including NOAC.22 Recommendations different from those in other guidelines were presented. These recommendations are: “For gastroenterological endoscopic procedures with a high risk of bleeding in patients on warfarin therapy, heparin replacement may increase the risk of postoperative bleeding. As an alternative to heparin replacement, continued warfarin treatment in patients where the international normalized ratio falls within the therapeutic range, or a temporary switch to NOAC in those with non-valvular atrial fibrillation, should be considered during endoscopic procedures.”22 These statements are notable because the existing guidelines recommend either the discontinuation of warfarin or heparin-bridge therapy according to the risk of thromboembolic events. On the contrary, the 2018 JGES guidelines suggest that the continuation of warfarin may be better than heparin-bridge therapy in patients at a high risk of thromboembolic events.
The joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) guidelines were published in 2018.23 The most important difference between these and other guidelines is that ESD was rated as an ultrahigh-risk procedure. A category for ultrahigh-risk procedures was added to the APAGE/APSDE guidelines because: (1) ESD is frequently performed in this area of the world, (2) many relevant studies were conducted in Asia, and (3) the opinions and clinical practice patterns for the management of antithrombotic agents significantly differ between Eastern and Western endoscopists.23,25,26 For high-risk procedures such as polypectomy, it is recommended that low-dose aspirin be continued in patients undergoing low-dose aspirin monotherapy or dual anti-platelet therapy. However, this recommendation does not apply to an ultrahigh-risk procedure such as ESD. In other words, the discontinuation of low-dose aspirin in patients who are scheduled for ESD may be considered. For anticoagulation therapy, heparin-bridge therapy is recommended for patients who are undergoing treatment with warfarin, but not those being treated with NOAC.
The recent guidelines have two concepts in common: (1) the risk of bleeding following ESD is high or ultrahigh and (2) antithrombotic agents should be discontinued based on the risk of thromboembolic events. However, there are issues with differences in the guidelines around the management of antithrombotic agents. These issues are: (1) the continuation of low-dose aspirin in patients at a high risk of thromboembolic events (such as those with dual antiplatelet therapy), (2) differences in the risk of bleeding or thromboembolic events between patients in Eastern and Western countries, and (3) the recommendation of heparin-bridge therapy during ESD in patients at a high risk of thromboembolic events. These issues will be discussed in the subsequent sections.
Although the APAGE/APSDE guidelines do not recommend the continuation of low-dose aspirin therapy during ultrahigh-risk procedures such as ESD, most guidelines suggest that low-dose aspirin therapy can be continued even during ESD. Such a recommendation is based on the results of several studies that showed that low-dose aspirin did not increase the post-ESD bleeding rate.27–29 A meta-analysis found that aspirin did not significantly increase post-ESD bleeding (odds ratio [95% confidence interval]: 1.81 [0.85–3.83]).30 Considering that thromboembolic events usually result in more serious sequelae than post-ESD bleeding, the continuation of low-dose aspirin therapy during ESD is reasonable for patients at a high thromboembolic risk.
Given that a meta-analysis showed that low-dose aspirin had a tendency of increasing post-ESD bleeding in patients, the continued use of low-dose aspirin may be of concern in patients at a higher risk of bleeding, such as those undergoing dual antiplatelet therapy. In a study by Cho et al,31 which was included in the abovementioned meta-analysis, the post-ESD bleeding rate was 3.4% in aspirin non-users, 3.6% in aspirin users who discontinued the use of aspirin, and 21.1% in aspirin users who continued using aspirin. The authors concluded that aspirin should be discontinued in patients at a low risk for thromboembolic diseases to minimize bleeding complications.31 However, the findings of the aforementioned study should be interpreted with caution because 36.8% of patients in the group that continued using aspirin compared to only 5.4% of patients in the group that discontinued the use of aspirin underwent dual antiplatelet therapy. Although the administration of antiplatelet agents other than aspirin was discontinued at least seven days before ESD and was resumed seven days after the ESD, the high post-ESD bleeding rate in the group that continued using aspirin might be due to other antiplatelet agents. In a study by Sanomura et al,27 similar numbers of patients who were taking either antiplatelet agents or anticoagulants were included in the low-dose aspirin continuation and discontinuation groups (32% in each group). In the aforementioned study, the post-ESD bleeding rate did not differ between the groups (continuation 3.6% vs discontinuation 4.8%,
Harada et al,32 in a recent study, evaluated the impact of low-dose aspirin continuation during ESD according to the dual antiplatelet therapy. In their study, the continuation of low-dose aspirin did not increase post-ESD bleeding (continuation 10.7% vs discontinuation 10.3%,
Concerns that the continuation of aspirin may increase the risk of post-ESD bleeding have been noted in the APAGE/APSDE guidelines. The guidelines recommends the interruption of all antithrombotic agents during ultrahigh-risk procedures provided that the perceived benefits of the procedure outweigh the patient’s thromboembolic risk.23 As mentioned earlier, ultrahigh-risk procedures were defined in the APAGE/APSDE guidelines for several reasons, including the difference in clinical practices between Eastern and Western endoscopists during the management of antithrombotic agents. Lee et al25 conducted a study on this issue, which involved 105 Eastern and 106 Western endoscopists. In the study, Eastern endoscopists usually discontinued aspirin more than seven days before polypectomy (76.3%), while 39.6% of Western endoscopists did not stop the use of aspirin before polypectomy. Additionally, Eastern endoscopists resumed aspirin administration one to three days after polypectomy (44.8%), while Western endoscopists resumed aspirin administration on the day of polypectomy (35.9%). Interestingly, more Eastern than Western endoscopists (22.4% vs 8.1%,
Traditionally, heparin-bridge therapy during the perioperative period was thought to be necessary to minimize thromboembolic risk due to the discontinuation of warfarin during this period. Most of the current guidelines, including the APAGE/APSDE guidelines, recommend heparin-bridge therapy during the period of warfarin discontinuation if patients have a high thromboembolic risk.17,20,23 However, heparin-bridge therapy increases the risk of post-ESD bleeding from 4.2 to 34.4 times.37–39 Additionally, there is no consensus on whether heparin-bridge therapy is an effective strategy. Recently, an interesting prospective observational study on this issue was conducted by Harada et al40 They investigated the differences in clinical outcomes, including post-ESD bleeding, operation time, and length of hospital stay, between the continuous use of low-dose warfarin and heparin-bridge therapy in patients. Although the post-ESD bleeding rate did not differ between the groups, it tended to be lower in the continuous use of low-dose warfarin group than in the heparin-bridge therapy group (9.1% vs 21.7%,
The effect of the continuous use of warfarin was also investigated in the field of cardiology. In a randomized-controlled trial performed by Birnie et al,41 the continuous use of warfarin during pacemaker or implantable cardioverter-defibrillator surgery markedly reduced the incidence of clinically significant device-pocket hematoma compared to heparin-bridge therapy (16.0% vs 3.5%,
Although current guidelines cover esophageal, gastric, and colorectal ESD, the most studied type is gastric ESD. Few studies are available on colorectal ESD and there is no study on esophageal ESD and the use of antithrombotic agents.12,20,43 Presently, antithrombotic agents in esophageal or colorectal ESD should be selected based on the results of studies on gastric ESD.
In this review, guideline recommendations for the management of antithrombotic agents in patients who undergo ESD were discussed. Because ESD is a high-risk procedure, thienopyridine derivatives may be discontinued to reduce the risk of post-ESD bleeding. However, in patients undergoing dual antiplatelet therapy, switching to a single low-dose aspirin therapy can be considered when thienopyridine derivatives are discontinued during the perioperative period. Most of the recent guidelines support the continuous use of low-dose aspirin even in patients who undergo ESD. However, there is still a concern about the increased risk of bleeding with the use of low-dose aspirin in patients undergoing dual antiplatelet therapy, especially in the Asian population.
In patients receiving anticoagulants, either warfarin or NOAC can be discontinued depending on the risk of thromboembolic events. For patients at a high risk of thromboembolic events, most current guidelines recommend the discontinuation of warfarin and heparin-bridge therapy. However, the continuous use of warfarin can also be considered in patients who undergo ESD, as recommended in the JGES guidelines.22
No potential conflict of interest relevant to this article was reported.
© The Society of Gastrointestinal Intervention. Powered by INFOrang Co., Ltd.